Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B5190f9d629ea53d3a3253a9bf8aeddf7> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B5190f9d629ea53d3a3253a9bf8aeddf7 NCIT_P378 "NCI" @default.
- B5190f9d629ea53d3a3253a9bf8aeddf7 type Axiom @default.
- B5190f9d629ea53d3a3253a9bf8aeddf7 annotatedProperty IAO_0000115 @default.
- B5190f9d629ea53d3a3253a9bf8aeddf7 annotatedSource NCIT_C102753 @default.
- B5190f9d629ea53d3a3253a9bf8aeddf7 annotatedTarget "A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy." @default.